SCHEMBL3904388

SCHEMBL3904388

COCCOc1ccc(C(=O)Nc2cccnc2C(=O)Nc2ccc(Cl)cn2)c(OCC(C)(C)CNC(=O)OC(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 13/20 0.46
NPC1 O15118 4/20 0.41
RAB9A P51151 4/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
KDM4E B2RXH2 1/20 0.40
IRAK4 Q9NWZ3 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
NFKB1 P19838 1/20 0.38
CASP3 P42574 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SENP8 Q96LD8 1/20 0.38
SENP7 Q9BQF6 1/20 0.38
SENP6 Q9GZR1 1/20 0.38
METAP1 P53582 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3904715 0.94 F10 (0.40) F10NPC1RAB9AMEN1KMT2A
SCHEMBL3904295 0.91 F10 (0.48) F10NPC1RAB9AMEN1KMT2A
SCHEMBL13898988 0.88 F10 (0.49) F10NPC1RAB9AMEN1KMT2A
SCHEMBL4270064 0.88 NPC1 (0.53) F10NPC1RAB9AMEN1KMT2A
SCHEMBL4269473 0.87 F10 (0.40) F10NPC1RAB9AMEN1KMT2A
SCHEMBL4279529 0.87 F10 (0.44) F10NPC1RAB9AMEN1KMT2A
Trifluoroacetic Acid SCHEMBL3910383 0.85 F10 (0.46) F10NPC1RAB9AMEN1KMT2A
SCHEMBL3902384 0.85 F10 (0.41) F10NPC1RAB9AMEN1KMT2A
Trifluoroacetic Acid SCHEMBL3909490 0.85 F10 (0.46) F10NPC1RAB9AMEN1KMT2A
SCHEMBL3912778 0.85 F10 (0.43) F10NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7511066-B2 Antithrombotic aromatic ethers ELI LILLY AND COMPANY (US) 2009-03-31 US disclosed
US-20070027185-A1 Antithrombotic aromatic ethers ELILILLY AND COMPANY (US) 2007-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027185-A1 Antithrombotic aromatic ethers F2, F11, TFPI F10 14/4885NPC1 2550/4885RAB9A 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.